For the ones closest to you,
and everyone around the world.
With a wish to extend the love we have for our dearest ones to everyone across the globe,
Mitsubishi Tanabe Pharma is striving to be a global research-driven pharmaceutical company.

What's New

  • RSS
  • About RSS
  • News Release List
  • Topics List
September 19, 2014 Release TELAVIC 250mg Tablets, Antiviral Approval of Additional indication for Chronic Hepatitis C Genotype 2PDF
September 5, 2014 Topics Mitsubishi Tanabe Pharma Corporate Report 2014
September 2, 2014 Release Launch of CANAGLU Tablets 100mg A SGLT2 inhibitor for Type2 Diabetes MellitusPDF
August 20, 2014 Release MITSUBISHI TANABE PHARMA CORPORATION AND ASTRAZENECA ANNOUNCE RESEARCH COLLABORATION IN DIABETIC NEPHROPATHYPDF
July 29, 2014 Topics IR Meeting for FY2014 1st Quarter Business Results[Material] [Audio]
⇒[Q&A](August 5, 2014)
July 29, 2014 Release Announcement of FY2014 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
July 4, 2014 Release Marketing and Manufacturing Approval in Japan Received for CANAGLU Tablets 100mgPDF
June 30, 2014 Release Notice regarding conclusion of a basic agreement for the transfer of the Kashima Plant of Mitsubishi Tanabe Pharma Factory Ltd.PDF
June 30, 2014 Release Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS)PDF
June 20, 2014 Topics Notice of Resolution of the 7th Ordinary General Meeting of Shareholders
⇒Results of the Exercise of Voting Rights(June 23, 2014)
June 16, 2014 Release Positive Phase 3 Results of Canagliflozin in Japanese Patients with Type 2 Diabetes at American Diabetes AssociationPDF
May 30, 2014 Release Name Change of Group Company in ChinaPDF
May 29, 2014 Release Announcement of Merger (Simplified Merger and Short form Merger) of Consolidated SubsidiaryPDF
May 29, 2014 Topics Notice of Convocation of the 7th Ordinary General Meeting of Shareholders
May 28, 2014 Release Name Change of Consolidated Subsidiaries in EuropePDF
May 9, 2014 Topics IR Meeting for FY2013 Business Results[Material] [Audio]
⇒[Q&A](May 19, 2014)
May 8, 2014 Release Announcement of Financial Results for FY2013
⇒R&D Pipeline "State of New Product Development"
April 23, 2014 Release Change of Representative Directors and PersonnelPDF
April 22, 2014 Topics R&D "Clinical Trial Information"
February 6, 2014 Release Change of Representative DirectorsPDF
February 3, 2014 Topics Conference Call for FY2013 3rd Quarter Business Results [Material] [Audio]
⇒[Q&A](February 10, 2014)
February 3, 2014 Release Announcement of FY2013 3rd Quarter Financial Results PDF
⇒R&D Pipeline "State of New Product Development"
February 3, 2014 Release MT-4666 in Alzheimer’s Disease
Start of Global Phase 3 Clinical Trial Program, COGNITIV ADPDF
January 16, 2014 Release TELAVIC 250mg Tablets, Antiviral
Application for additional Indication for Chronic Hepatitis C Genotype 2PDF
December 20, 2013 Release TENELIA 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination TherapyPDF
November 1, 2013 Topics IR Meeting for FY2013 2nd Quarter Business Results[Material] [Audio]
⇒[Q&A](November 8, 2013)
October 30, 2013 Release Announcement of FY2013 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
October 21, 2013 Topics CSR Report 2013
September 30, 2013 Release Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law of JapanPDF
September 25, 2013 Release Revision to 2Q Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2014PDF
September 19, 2013 Release Mitsubishi Tanabe Pharma to Open Singapore OfficePDF
September 19, 2013 Release Notice Regarding Completion of Acquisition of Shares of Medicago, Inc., a Pharmaceutical Company Based in Canada, Which Has Become a Subsidiary of Mitsubishi Tanabe PharmaPDF
September 9, 2013 Release Tanabe Indonesia to Construct New Production Facility in IndonesiaPDF
August 8, 2013 Release Notice Regarding Arbitration Award in Dispute with Janssen Biotech, Inc.PDF
August 6, 2013 Topics Annual Report 2013
August 6, 2013 Release Tianjin Tanabe Seiyaku to Construct New Production Facility in ChinaPDF
August 1, 2013 Release Notice regarding the reorganization of Mitsubishi Tanabe Pharma Factory Ltd.'s domestic production sites and the conclusion of a basic agreement regarding the transfer of its Ashikaga PlantPDF
July 31, 2013 Topics Conference Call for FY2013 1st Quarter Business Results [Material] [Audio]
⇒[Q&A](August 7, 2013)
July 31, 2013 Release Announcement of FY2013 1st Quarter Financial Results PDF
⇒R&D Pipeline "State of New Product Development"
July 12, 2013 Release Notice regarding the acquisition of Medicago Inc.PDF
June 27, 2013 Release VIVUS gains MAA approval for TA-1790 in the EUPDF
June 21, 2013 Topics Notice of Resolution of the 6th Ordinary General Meeting of Shareholders
⇒Results of the Exercise of Voting Rights(June 24, 2013)
June 14, 2013 Release Approval for Additional Indication for Atrial Fibrillation (Tachycardiac ) MAINTATE Tablets: Selective β1 BlockerPDF
May 30, 2013 Topics Notice of Convocation of the 6th Ordinary General Meeting of Shareholders
May 27, 2013 Release New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 DiabetesPDF
May 9, 2013 Topics IR Meeting for FY2012 Business Results[Material] [Audio]
⇒[Q&A](May 20, 2013)
May 8, 2013 Release Announcement of Financial Results for FY2012
⇒R&D Pipeline "State of New Product Development"
April 30, 2013 Release Change of DirectorsPDF
April 3, 2013 Release Launch of BindRen for Treatment of Hyperphosphatemia in Germany and AustriaPDF
April 1, 2013 Release Transfer of Tanabe Europe’s sharesPDF
April 1, 2013 Release U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 DiabetesPDF
February 28, 2013 Release Approval for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular diseasePDF
February 26, 2013 Release TENELIA 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination TherapyPDF
February 21, 2013 Topics Information Meeting [Material][Audio]
⇒[Q&A](March 1, 2013)
February 21, 2013 Release Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump InhibitorPDF
February 1, 2013 Topics Conference Call for FY2012 3rd Quarter Business Results [Material][Audio]
⇒[Q&A](February 8, 2013)
February 1, 2013 Release Announcement of FY2012 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
January 29, 2013 Release BindRen Granted Marketing Authorization in Europe for Treatment of HyperphosphatemiaPDF
October 29, 2012 Topics Conference Call for FY2012 2nd Quarter Business Results [Material][Audio]
⇒[Q&A](November 5, 2012)
October 29, 2012 Release Announcement of FY2012 2nd Quarter Financial Results PDF
⇒R&D Pipeline "State of New Product Development"
October 26, 2012 Release Launch of TETRABIK Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined VaccinePDF
October 19, 2012 Release Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd.PDF
October 11, 2012 Topics CSR Report 2012
October 10, 2012 Release Outcome of Global Phase III (EPPIC) StudiesPDF
October 1, 2012 Release Outsourcing of Logistics Operations
September 28, 2012 Release Application for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular diseasePDF
September 20, 2012 Release Launch of "Simponi”, a human TNFα monoclonal antibody in IndonesiaPDF
September 13, 2012 Release MAINTATE Tablets: Selective β1 Antagonist
Notice regarding application for additional indication for chronic atrial fibrillationPDF
August 31, 2012 Release Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or MetronidazolePDF
August 31, 2012 Release Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro CorporationPDF
August 28, 2012 Release Launch of TENELIA 20mg Tablets
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from JapanPDF
August 21, 2012 Topics Annual Report 2012
July 31, 2012 Topics Conference Call for FY2012 1st Quarter Business Results [Material][Audio]
⇒[Q&A](July 31, 2012)
July 31, 2012 Release Announcement of FY2012 1st Quarter Financial Results PDF
⇒R&D Pipeline "State of New Product Development"
July 23, 2012 Release Launch of Tranquilizer, DEPAS TABLETS 0.25 mgPDF
July 6, 2012 Release Launch of Argatroban, a Selective Antithrombin Agent, in UKPDF
June 29, 2012 Release Marketing and Manufacturing Approval Received for TENELIA 20mg Tablets
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from JapanPDF
June 22, 2012 Topics Notice of Resolution of the 5th Ordinary General Meeting of Shareholders
⇒Results of the Exercise of Voting Rights(June 25, 2012)
June 22, 2012 Topics IR "Financial Data"
June 6, 2012 Release Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan
June 1, 2012 Release Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary HyperparathyroidismPDF
May 15, 2012 Release Notice Regarding Transfer of Fine Chemical OperationsPDF
May 14, 2012 Topics R&D "Clinical Trial Information"
May 10, 2012 Topics IR Meeting for FY2011 Business Results[Material] [Audio]
⇒[Q&A](May 18, 2012)
May 9, 2012 Release Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in IndonesiaPDF
May 8, 2012 Release Announcement of Financial Results for FY2011 PDF
⇒R&D Pipeline "State of New Product Development"
May 8, 2012 Release Notice of Dividend of Retained EarningsPDF
May 8, 2012 Release New Organization in Plasma Fractionation Operations
Establishment of “Japan Blood Products Organization”PDF
May 8, 2012 Release Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody
A New Option to Shorten Infusion TimePDF
May 8, 2012 Release Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody
Lifting of Condition on Approval for PsoriasisPDF
May 7, 2012 Release VIVUS gains NDA approval for TA-1790 in the US
March 29, 2012 Release Launch of "SIMPONI”, a human TNFα monoclonal antibody in TaiwanPDF
March 21, 2012 Release “IMUSERA Capsules 0.5mg” Multiple Sclerosis Treatment AgentNotice regarding revision of “warnings” and “important basic precautions” sections of prescribing information PDF
March 7, 2012 Release Conclusion of Research Collaboration Agreement for Next-Generation VaccinesPDF
March 6, 2012 Release Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Alliance to Contribute to the Treatment of Diabetes in Japan
Companies conclude joint sales agreement for two treatments
for type 2 diabetes mellitus - MP-513 and TA-7284 PDF
January 31, 2012 Topics Conference Call for FY2011 3rd Quarter Business Results [Material][Audio]
⇒[Q&A](February 6, 2012)
January 31, 2012 Release Announcement of FY2011 3rd Quarter Financial Results PDF
⇒R&D Pipeline "State of New Product Development"
January 16, 2012 Release Conclusion of Licensing Agreement for Hib VaccinePDF
December 1, 2011 Release Dainippon Sumitomo Pharma and Yoshitomiyakuhin
terminate co-promotion of antipsychotics, LONASEN and LULLANPDF
November 25, 2011 Release Launch of "IMUSERA Capsules 0.5mg"Japan's First Oral Dosing Multiple Sclerosis Treatment with Novel Mode of ActionPDF
November 25, 2011 Release Launch of Antiviral Agent "TELAVIC Tablets 250 mg"Novel Mode of Action for Chronic Hepatitis C TreatmentPDF
November 25, 2011 Release Approval of Additional Indication for MODIODAL Tablets 100 mg
a Sleep Disorder TreatmentPDF
November 21, 2011 Topics CSR Report 2011
November 18, 2011 Release Notice of postponement of integrating the plasma fractionation operations of
the Japanese Red Cross Society and Mitsubishi Tanabe Pharma CorporationPDF
October 31, 2011 Topics Conference Call for FY2011 2nd Quarter Business Results [Material][Audio]
[Q&A](November 7, 2011)
October 31, 2011 Release Announcement of FY2011 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
October 31, 2011 Release Revision of Dividend of Retained Earnings and Year-end Dividend ForecastPDF
October 21, 2011 Release Toray, Mitsubishi Tanabe Pharma Reach North American License Agreement on Antipruritic Agent, TRK-820PDF
October 19, 2011 Topics IR Meeting for Medium-Term Management Plan[Material][Audio]
[Q&A](October 28, 2011)
October 17, 2011 Release Formulation of Medium-Term Management Plan 11-15 New Value Creation PDF
<Presentation Material>
September 26, 2011 Release Approval for "IMUSERA Capsules 0.5mg" Japan's First Once-Daily Oral Dosing Multiple Sclerosis TreatmentPDF
September 26, 2011 Release Approval for TELAVIC 250mg Tablet
Novel Mode of Action for Chronic Hepatitis C TreatmentPDF
September 26, 2011 Release Approval for Additional Indication of Generalized Myasthenia GravisVenoglobulinIH 5% for Intravenous Injection,a Human Immunoglobulin Preparation Derived from Donated PlasmaPDF
September 22, 2011 Topics Presentation Material for Deutsche Securities Japan Pharmaceutical Conference 2011PDF
September 15, 2011 Release Launch of "SIMPONI (golimumab) Subcutaneous Injection 50mg Syringe"
A Treatment of Rheumatoid ArthritisPDF
September 1, 2011 Release New Drug Application Filed in Japan for MP-513
a Type 2 Diabetes TreatmentPDF
August 31, 2011 Topics Annual Report 2011
August 31, 2011 Topics R&D "Clinical Trial Information"
August 22, 2011 Release Mitsubishi Tanabe Pharma Prevails in U.S. Argatroban Patent LitigationPDF
August 17, 2011 Release Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal-Antibody
Approval for a Partial Change of Dosage and Usage in Crohn’s DiseasePDF
August 17, 2011 Topics R&D "Clinical Trial Information"
August 4, 2011 Topics Conference Call for FY2011 1st Quarter Business Results [Q&A〕PDF
July 29, 2011 Topics Conference Call for FY2011 1st Quarter Business Results [Material〕[Audio]
July 29, 2011 Release Announcement of FY2011 1st Quarter Financial Results PDF
⇒R&D Pipeline "State of New Product Development"
July 29, 2011 Release Revision to First Half and Full Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2012PDF
July 21, 2011 Release The NHI Drug Price Listing and Launch of an Anti-depressant, Lexapro 10mgPDF
July 19, 2011 Release Notice Regarding a Business Suspension Order for the Ashikaga Plant of Mitsubishi Tanabe Pharma Factory Ltd. and a Business Improvement Order for Mitsubishi Tanabe Pharma CorporationPDF
July 1, 2011 Release Approval for "SIMPONI Subcutaneous Injection 50mg Syringe(Generic Name: Golimumab)" for Treatment of Rheumatoid ArthritisPDF
June 22, 2011 Topics Notice of Resolution of the 4th Ordinary General Meeting of Shareholders
June 17, 2011 Release Notice of a basic agreement between the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation regarding the commencement of discussions about the integration of their plasma fractionation operationsPDF
June 2, 2011 Release AZANIN Tablets 50mg, Immunosuppressant Approval for Additional Indication for Refractory Rheumatic Diseases PDF
May 27, 2011 Release Launch of Anti-allergy Agent, Bepotastine Besilate in China and IndonesiaPDF
May 20, 2011 Release Approval for Additional Indication for selective β1 antagonist, MAINTATE Tablets 0.625, 2.5, and 5 and Launch of MAINTATE Tablets 0.625PDF
May 20, 2011 Release Approval for Additional Indications for the Selective Antithrombin Agents,Novastan HI Injection 10 mg/2mL and Slonnon HI Injection 10 mg/2mLPDF
May 20, 2011 Release Approval for Additional Indication of Anti-D Human Immunoglobulin I.M.1000-BENESIS (Dry anti-Rho(D) Immune Human Globulin)PDF
May 19, 2011 Topics IR Meeting for FY2010 Business Results [Q&A〕PDF
May 12, 2011 Topics IR Meeting for FY2010 Business Results[Material] [Audio]
May 10, 2011 Release Announcement of Financial Results for FY2010
⇒R&D Pipeline "State of New Product Development"
May 10, 2011 Release Partial Amendment of the Articles of IncorporationPDF
April 27, 2011 Release Change of Directors, and OrganizationPDF
April 27, 2011 Release Summary of the Quality Control IncidentPDF
April 11, 2011 Release Impact of the Great East Japan Earthquake (3rd Notice)PDF
March 30, 2011 Release Impact of the 2011 off the Pacific coast of Tohoku Earthquake (2nd Notice)PDF
March 28, 2011 Release Novartis receives European Commission approval for FTY720, the first oral multiple
sclerosis treatment for use in the EUPDF
March 15, 2011 Release Impact of the 2011 off the Pacific coast of Tohoku Earthquake
March 14, 2011 Release Mitsubishi Tanabe Pharma Supports Japan Earthquake Relief EffortsPDF
⇒Mitsubishi Chemical Holdings Group:Aid for Areas Affected
March 11, 2011 Release Open innovation laboratory for drug discovery and development by Mitsubishi Tanabe Pharma and Kyoto University
-Basic and clinical research project for CKD drugs-PDF
March 7, 2011 Release Transfer of Marketing Rights of 5 Long-term Listed Drugs to Tanabe Seiyaku HanbaiPDF
January 28, 2011 Release Application Submitted in Japan for MP-424
a Novel Chronic Hepatitis C TreatmentPDF
January 28, 2011 Release Nycomed and Mitsubishi Tanabe Pharma to Terminate Collaborative Development of APTA-2217, Roflumilast for Treatment of Respiratory Diseases in Japanese MarketPDF
January 26, 2011 Release Notice Regarding Voluntary Recall of Three Drugs (Six Dosage Sizes)PDF
January 11, 2011 Release "Kremezin", Drug for Chronic Renal Failure Transfer of Marketing Rights in JapanPDF
December 21, 2010 Release Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South KoreaPDF
December 20, 2010 Release Application Submitted in Japan for FTY720, a Novel Multiple Sclerosis TreatmentPDF
December 14, 2010 Release Commencement of R&D Partnership with Anaphore for Atrimer Technology (Novel Trivalent Proteins)PDF
December 9, 2010 Topics R&D Meeting [Q&A]PDF
December 1, 2010 Release Removal of Grace PeriodPDF
December 1, 2010 Topics R&D Meeting[Material] [Audio]
October 29, 2010 Release Notice Regarding Change in the Number of Shares Constituting One Trading Unit and Partial Amendments to the Articles of IncorporationPDF
September 28, 2010 Release Novartis gains NDA approval for FTY720 in the USPDF
June 16, 2010 Release Notice Regarding Submission of Business Improvement PlansPDF
April 13, 2010 Release Notice Regarding Administrative Action Related to Violation of Pharmaceutical Affairs LawPDF
January 7, 2010 Release Conclusion of Co-marketing Agreement for an Anti-Depressant, Escitalopram in JapanPDF
December 21, 2009 Release Name Change of Pharmaceutical Manufacturing & Sales Subsidiaryin Korea (Welfide Korea Co., Ltd.)PDF
October 13, 2009 Release Establishment of Pharmaceutical Sales & Marketing Company and Reorganization of Group Companies in the U.S.PDF
April 10, 2009 Release Standard for our company’s payment burdens related to fees required for benefit payments and other operations, based on “the Special Relief Law Concerning the Payment of Benefits to Relieve the Patients of Hepatitis C (abbreviated title)”PDF
March 24, 2009 Release Withdrawal of Marketing Authorization for Recombinant Human Serum Albumin Preparation “Medway Injection 5%” and Voluntary Recall of “Medway Injection 5%” and “Medway Injection 25%”
September 19, 2008 Release The Basic Agreement to Be Concluded with the National Plaintiffs Group on the HCV Class ActionPDF
May 7, 2008 Release Announcement of Corporate Behavior Charter and Medium-Term Management PlanPDF
October 1, 2007 Release Announcement of the Establishment of Mitsubishi Tanabe Pharma CorporationPDF

Information

Share Price Information